Request Trial
istock-645671352_kittisakjirasittichai
KittisakJirasittichai / iStockphoto.com
17 October 2018Pharma

SPC waiver: good intentions, but not the right deal?

Striking the perfect balance between incentivising innovation in drug development and widening access to medicines through generic competition is perhaps an unobtainable aim, but it’s an ideal that legislators and regulators must strive towards.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Pharma
Dr Reddy’s eyes appeal stakes as Boehringer hearing ends
22 October 2026   Questions over what Boehringer’s patents actually proved dominated the final day of the hearing, but a push for a further finding raised the stakes, with a possible appeal threatening to keep Dr Reddy’s off the market even if it won.
Pharma
Amarin and Hikma call time on six-year skinny label fight
22 October 2026   Following a major US Supreme Court win for generics, the landmark dispute has finally come to an end. A new filing brings closure to a case that raised questions over skinny labelling and induced patent infringement.
Pharma
Boehringer accuses Dr Reddy’s of ‘weaponising’ plausibility
20 October 2026   In closing arguments last week, the drugmaker urged the UK Patents Court to reject an overly critical approach to plausibility and consider what its patents disclose when read as a whole rather than individually.


Editor's picks

WATCH: Medmix global IP head on building business-focused IP teams
In-house counsel
WATCH: Medmix global IP head on building business-focused IP teams
21 October 2026

Editor's picks

In-house counsel
WATCH: Medmix global IP head on building business-focused IP teams
21 October 2026
MedTech
Boston Scientific expands dispute with J&J unit over cardiac-access technology
12 October 2026
Pharma
Dr Reddy’s v Boehringer: Data gaps take centre stage in courtroom
6 October 2026
In-house counsel
WATCH: Genevant IP director on tackling UPC-EPO opposition divide
1 October 2026
Pharma
Lilly loses Fed Circ rehearing bid, sparking enablement questions
1 October 2026
Pharma
Takeda sees off UK challenge to Elvanse SPC
28 September 2026

More features

Dr Reddy’s eyes appeal stakes as Boehringer hearing ends
Amarin and Hikma call time on six-year skinny label fight
Boehringer accuses Dr Reddy’s of ‘weaponising’ plausibility
Boehringer and Dr Reddy’s spar over plausibility as trial wraps up
Haynes Boone expands in California with new office
Accord’s generic hopes dashed in cyanide antidote ruling
Novo’s semaglutide protection weakens after European ruling
Brazilian firm appoints patent strategist to lead department